Achilles Therapeutics (NASDAQ: ACHL)
$0.92 N/A ( 0% ) 14.2K
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.